Breaking News

Sunday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fly Intel: Top five weekend stock stories » 20:09
04/05/20
04/05
20:09
04/05/20
20:09
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

, BA

Boeing

$124.59 /

+1.38 (+1.12%)

, FB

Facebook

$154.19 /

-3.92 (-2.48%)

, TWTR

Twitter

$23.08 /

+0.07 (+0.30%)

, GOOG

Alphabet

$1,097.93 /

-25.87 (-2.30%)

, GOOGL

Alphabet Class A

$1,092.51 /

-24.78 (-2.22%)

, UAL

United Airlines

$22.89 /

-0.53 (-2.26%)

, CMCSA

Comcast

$33.94 /

-0.43 (-1.25%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, T

AT&T

$27.46 /

-1.305 (-4.54%)

, VZ

Verizon

$54.72 /

-0.52 (-0.94%)

, ABT

Abbott

$79.50 /

+0.075 (+0.09%)

, CVX

Chevron

$75.15 /

-1.07 (-1.40%)

, HRL

Hormel Foods

$48.37 /

+0.72 (+1.51%)

, JNJ

Johnson & Johnson

$134.13 /

+1.05 (+0.79%)

, KMB

Kimberly-Clark

$130.02 /

+0.58 (+0.45%)

, MDT

Medtronic

$86.17 /

+0.02 (+0.02%)

, PG

Procter & Gamble

$115.10 /

+0.68 (+0.59%)

, TROW

T. Rowe Price

$95.02 /

-2.13 (-2.19%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Gilead Sciences (GILD) said it is donating 1.5M doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients. In an open letter, Chairman and CEO Daniel O'Day said that the drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms. "Our existing supply, including finished product ready for distribution as well as investigational medicine in the final stages of production, amounts to 1.5 million individual doses. Depending on the optimal duration of treatment, which is something we are studying in clinical trials, this supply could equate to well over 140,000 treatment courses for patients. [...] Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility." 2. Boeing (BA) announced that it is extending the temporary suspension of production operations at all Puget Sound area and Moses Lake sites until further notice. "These actions are being taken in light of the company's continuing focus on the health and safety of employees, current assessment of the spread of COVID-19 in Washington state, the reliability of the supply chain and additional recommendations from government health authorities," the plane maker said in a statement Sunday night. 3. Across the media landscape, advertising is disappearing, one more casualty of the global economic shutdown, and new technology won't be a savior as this is an equal-opportunity problem across print, TV, digital, radio, and outdoor advertising, Eric Savitz wrote in this week's edition of Barron's. Even the most prominent ad buyers lack reasons, and often the means, to buy ads, the author notes, while many of the small and medium-size businesses that buy online ads are struggling to stay solvent. Both Facebook (FB) and Twitter (TWTR) have already warned that they will take a hit from the downturn, and Alphabet's Google (GOOGL) no doubt is seeing the same effects, but so far hasn't discussed the matter, the publication adds. 4. United Airlines (UAL) is cutting nearly 90% of its New York-area flying, as public health officials predicted that the city will reach the peak of its novel coronavirus outbreak in the coming days, The Wall Street Journal's Alison Sider reported. The airline said the reductions set to remain in place for at least three weeks will mean substantially fewer employees will need to show up each day, though workers will continue to receive pay and benefits, the author noted. 5. Comcast (CMCSA), AT&T (T), Verizon (VZ), Abbott Laboratories (ABT), Chevron (CVX), Hormel Foods (HRL), Johnson & Johnson (JNJ), Kimberly-Clark (KMB), Medtronic (MDT), Procter & Gamble (PG), and T. Rowe Price (TROW) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Saturday
Periodicals
J&J, Chevron among names with safe dividends for now, Barron's says » 10:04
04/04/20
04/04
10:04
04/04/20
10:04
TROW

T. Rowe Price

$95.02 /

-2.13 (-2.19%)

, PG

Procter & Gamble

$115.10 /

+0.68 (+0.59%)

, MDT

Medtronic

$86.17 /

+0.02 (+0.02%)

, KMB

Kimberly-Clark

$130.02 /

+0.58 (+0.45%)

, JNJ

Johnson & Johnson

$134.13 /

+1.05 (+0.79%)

, HRL

Hormel Foods

$48.37 /

+0.72 (+1.51%)

, CVX

Chevron

$75.15 /

-1.07 (-1.40%)

, ABT

Abbott

$79.50 /

+0.075 (+0.09%)

Among the 64 S&P 500…

Among the 64 S&P 500 Dividend Aristocrats, the dividends of Abbott Laboratories (ABT), Chevron (CVX), Hormel Foods (HRL), Johnson & Johnson (JNJ), Kimberly-Clark (KMB), Medtronic (MDT), Procter & Gamble (PG), and T. Rowe Price (TROW) look safe for now, thanks in part to relatively low debt loads, Lawrence Strauss writes in this week's editions of Barron's. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Recommendations
T. Rowe Price growth driver threatened by market selloff, says JPMorgan » 09:02
03/30/20
03/30
09:02
03/30/20
09:02
TROW

T. Rowe Price

$98.51 /

-2.81 (-2.77%)

The equity market selloff…

The equity market selloff threatens the key driver of T. Rowe Price's strong relative organic growth - the growth from its target date fund business, JPMorgan analyst Kenneth Worthington tells investors in a research note. T. Rowe has a more aggressive "glide path," driving a higher allocation to equities than peers, says the analyst. In good equity markets, T. Rowe target date funds outperform, but when equity markets depreciate, T. Rowe funds lose alpha, says Worthington. The analyst keeps an Underweight rating on T. Rowe Price shares with a $97 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
T. Rowe Price downgraded to Sell from Neutral at Goldman Sachs » 06:29
03/24/20
03/24
06:29
03/24/20
06:29
TROW

T. Rowe Price

$85.41 /

-4.905 (-5.43%)

Goldman Sachs analyst…

Goldman Sachs analyst Alexander Blostein downgraded T. Rowe Price to Sell from Neutral with a price target of $84, down from $120. The company's "significant" revenue, margin and earnings declines amid deteriorating markets and risks of rising outflows are not captured in the current stock price, Blostein tells investors in a research note. While T. Rowe is on a stronger footing than most of its asset manager peers, the company is not immune to the rapidly deteriorating macro conditions, leaving a more negative risk/reward to the stock, contends the analyst.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
T. Rowe Price price target lowered to $119 from $152 at Wells Fargo » 07:53
03/16/20
03/16
07:53
03/16/20
07:53
TROW

T. Rowe Price

$107.33 /

+16.51 (+18.18%)

Wells Fargo analyst…

Wells Fargo analyst Christopher Harris lowered the firm's price target on T. Rowe Price to $119 from $152 mainly on double-digit pullbacks for equity markets around the globe. The analyst keeps an Overweight rating on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
T. Rowe Price reports preliminary AUM $1.15T at February 29 » 08:32
03/11/20
03/11
08:32
03/11/20
08:32
TROW

T. Rowe Price

$112.63 /

+9 (+8.68%)

Client transfers from…

Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $0.9B in February and $3.7B for the quarter-to-date period ended February 29.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
LPL Financial nominates Edward Bernard for election to board of directors » 09:03
02/20/20
02/20
09:03
02/20/20
09:03
LPLA

LPL Financial

$97.59 /

+3.31 (+3.51%)

, TROW

T. Rowe Price

$139.15 /

+1.35 (+0.98%)

LPL Financial Holdings…

LPL Financial Holdings Inc. (LPLA) announced that James Riepe, a member of the company's board of directors since 2008, will not seek reelection after his current term expires at the 2020 annual meeting of stockholders. Edward Bernard will be nominated for election as a new independent director at the annual meeting, which will be held on May 6, 2020. Bernard holds a broad array of executive leadership experience in the wealth management industry, having most recently served as the vice chair of the board of directors of T. Rowe Price Group, Inc. (TROW).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
T. Rowe Price to host investor day » 08:55
02/19/20
02/19
08:55
02/19/20
08:55
TROW

T. Rowe Price

$137.80 /

+0.35 (+0.25%)

Investor day to be held…

Investor day to be held on February 19 at 9:30 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
T. Rowe Price to host investor day » 06:07
02/18/20
02/18
06:07
02/18/20
06:07
TROW

T. Rowe Price

$137.45 /

+1.08 (+0.79%)

Investor day to be held…

Investor day to be held on February 19 at 9:30 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
T. Rowe Price raises quarterly dividend 18.4% to 90c per share » 13:19
02/12/20
02/12
13:19
02/12/20
13:19
TROW

T. Rowe Price

$137.95 /

-0.66 (-0.48%)

T. Rowe Price Grou…

T. Rowe Price Grou announced that its Board of Directors has declared a quarterly dividend of 90c per share payable March 30, 2020 to stockholders of record as of the close of business on March 16, 2020. The quarterly dividend rate represents a 18.4% increase over the previous quarterly dividend rate of 76c per share. This will mark the 34th consecutive year since the firm's initial public offering that the company will have increased its regular annual dividend.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.